Richtlijn HIV
Deze pagina is het laatst bewerkt op 9 nov 2023 om 17:48. | Deze pagina is 58.239 maal bekeken.

Lijst met verwijzingen naar andere richtlijnen

Uit Richtlijnen HIV

(Verschil tussen bewerkingen)
Ga naar: navigatie, zoeken
 
(55 tussenliggende versies worden niet weergegeven)
Regel 1: Regel 1:
-
In onderstaande tabel staan verwijzingen naar andere richtlijnen opgesomd:  
+
In onderstaande lijst staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld:<br>
-
<br>  
+
'''Antiretrovirale therapie bij volwassenen'''<br>Wanneer beginnen?: <u>DHHS</u><br>Keuze van antiretrovirale behandeling bij naïeve volwassen met hiv: <u>DHHS</u><br>Tijdelijk onderbreken van antiretrovirale behandeling: <u>DHHS</u><br>Antiretrovirale behandeling bij voorbehandelde mensen met hiv: <u>DHHS</u><br>'''Monitoring''': <u>DHHS</u><br>Controles van mensen met hiv (polikliniek)<br>Bij eerste consult bij mensen met hiv<br>Eerste controle bij therapie-naïeve mensen na start van de antiretrovirale behandeling, 4-6 weken na start (op indicatie)<br>Controle van mensen met antiretrovirale behandeling<br>Controle van mensen zonder antiretrovirale behandeling<br>Spiegelbepaling: <u>EACS</u><br>Resistentiebepalingen: <u>DHHS</u><br>'''Diagnostiek en behandeling acute hiv-infectie''': <u>DHHS</u><br>'''Therapietrouwbevordering<br>Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode''': <u>DHHS, Landelijk HIV&nbsp;expositieprotocol neonaten, inclusief follow-up pasgeborene en kind</u>'''<br>Hiv-2 bij volwassenen: behandeling en monitoring<br>Bijzondere omstandigheden'''<br>Adviezen m.b.t. inname van anti-hiv middelen na braken<br>Adviezen m.b.t. inname van anti-hiv middelen bij vergeten van slikmoment<br>Marge tussen twee innames<br>Inname medicatie bij overschrijden tijdzones<br>Adviezen m.b.t. gebruik anti-hiv middelen door de sonde<br>Doseringen bij gestoorde leverfunctie<br>Doseringen bij gestoorde nierfunctie<br>Adviezen m.b.t. hiv-therapie bij mensen met een gastric bypass<br>'''Behandeling van hepatitis B/C virus coïnfectie bij mensen met hiv-1'''<br>Hepatitis B: <u>HBV richtsnoer</u><br>Hepatitis C: <u>HCV richtsnoer</u><br>HCC surveillance: <u>HBV richtsnoer</u><br>'''Behandeling van tuberculose bij mensen met een hiv-infectie''':<u>CPT</u><br>'''Screening en comorbiditeit'''<br>Screening cervixcarcinoom: <u>CIN</u><br>Screening anale premaligne afwijkingen<br>Screening overige comorbiditeit en bijwerkingen: <u>EACS</u><br>'''Geneesmiddeleninteracties''': <u>EACS</u>'''<br>Profylaxe en behandeling van opportunistische infecties''': <u>DHHS, nationale antibioticaboekje, SWAB, NVvP</u>'''<br>Transmissiemanagement'''<br>Prikaccidenten: <u>LCI</u><br>Seksaccidenten: <u>LCI</u><br>Discordante koppels<br>'''Vaccinatiebeleid'''<br>Influenza: <u>RIVM</u><br>Streptococcus pneumoniae (pneumokokken): <u>DHHS</u><br>Hepatitis A en B: <u>RIVM</u><br>Reizigers met hiv<br>Varicellazostervirus<br>COVID-19: <u>RIVM</u><br>'''Reizigersadvisering'''<br>Inname medicatie bij overschrijden tijdzones<br>Vaccinatie en profylaxe bij reizigers met hiv
-
{| cellspacing="0" cellpadding="0" border="1" style="mso-yfti-irow:0;mso-yfti-firstrow:yes" class="MsoTableGrid"
+
'''Achtergrondinformatie over de richtlijn en totstandkoming'''  
-
|-
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''Pagina'''  
+
-
| width="269" valign="top" style="width:201.9pt;border:solid windowtext 1.0pt; border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
Samenstelling werkgroep<br>Overzicht belangen werkgroepleden<br>Doelen en werkwijze<br>Wijzigingsoverzichten van de richtlijn<br>Lijst met verwijzingen naar andere richtlijnen
-
'''Verwijzing naar andere richtlijnen'''
+
-
 
+
-
|- style="mso-yfti-irow:1"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Richtlijn%20HIV"&gt;Hoofdpagina''' '''(=inhoudsopgave)&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span style="mso-bidi-font-weight:bold">
+
-
</span>
+
-
 
+
-
|- style="mso-yfti-irow:2"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span style="mso-bidi-font-weight:bold">
+
-
</span>
+
-
 
+
-
|- style="mso-yfti-irow:3"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%201.%20Achtergrondinformatie%20bij%20de%20ontwikkeling%20en%20herziening%20van%20deze%20richtlijn%20en%20inleiding"&gt;Hoofdstuk 1. Achtergrondinformatie bij de ontwikkeling en herziening van deze richtlijn''' '''en inleiding&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span style="mso-bidi-font-weight:bold">NVHB Richtlijn 2007</span>
+
-
 
+
-
|- style="mso-yfti-irow:4"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Procedure%20herziening"&gt;Procedure herziening&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
NVHB Richtlijn 2007
+
-
 
+
-
|- style="mso-yfti-irow:5"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Samenstelling%20kernwerkgroep"&gt;Samenstelling kernwerkgroep&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:6"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Overzicht%20belangen%20werkgroepleden"&gt;Overzicht belangen werkgroepleden&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:7"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Definities"&gt;Definities&lt;/a&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
 
+
-
 
+
-
|- style="mso-yfti-irow:8"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
Geschiedenis per pagina van deze richtlijn (= huidige pagina)
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:9"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:10"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%202.%20Therapie%20bij%20volwassenen"&gt;Hoofdstuk''' '''2. Therapie bij volwassenen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:11"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.1.%20Wanneer%20beginnen?"&gt;2.1. Wanneer beginnen?&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:12"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20wanneer%20starten"&gt;Onderbouwing wanneer starten&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
+
-
 
+
-
|- style="mso-yfti-irow:13"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%202.1"&gt;Literatuur 2.1&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:14"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.2.%20Keuze%20van%20antiretrovirale%20therapie%20bij%20na%C3%AFeve%20volwassen%20pati%C3%ABnten"&gt;2.2. Keuze van antiretrovirale therapie bij naïeve volwassen patiënten&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
+
-
 
+
-
|- style="mso-yfti-irow:15"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%202.2"&gt;Literatuur 2.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:16"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.3.%20Tijdelijk%20onderbreken%20van%20HAART"&gt;2.3. Tijdelijk onderbreken van HAART&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
+
-
 
+
-
|- style="mso-yfti-irow:17"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/T%C2%BD%20van%20antiretrovirale%20middelen"&gt;T½ van antiretrovirale middelen&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:18"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.4.%20Richtlijn%20anti-retrovirale%20therapie%20bij%20voorbehandelde%20pati%C3%ABnten"&gt;2.4. Richtlijn <span class="SpellE">anti-retrovirale</span> therapie bij <span class="SpellE">voorbehandelde</span> patiënten&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
+
-
 
+
-
|- style="mso-yfti-irow:19"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:20"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%203.%20Behandeling%20van%20HIV-1%20infectie%20bij%20kinderen"&gt;Hoofdstuk''' '''3. Behandeling van HIV-1 infectie bij kinderen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:21"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:22"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%204.%20Monitoring"&gt;Hoofdstuk''' '''4. Monitoring&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:23"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.1.%20Controles%20HIV-pati%C3%ABnten%20%28polikliniek%29"&gt;4.1. Controles HIV-patiënten (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:24"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bij%20eerste%20consult%20bij%20HIV-seropositieve%20pati%C3%ABnt%20%28polikliniek%29"&gt;Bij eerste consult bij <span class="SpellE">HIV-seropositieve</span> patiënt (polikliniek)&lt;/a&gt;&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bij%20instellen%20op%20antiretrovirale%20therapie%20%28polikliniek%29" _fcknotitle=true _fcksavedurl="Bij instellen op antiretrovirale therapie (polikliniek)"&gt;Bij instellen op antiretrovirale therapie (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:25"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Eerste%20controle%20na%20instellen%20op%20anti-retrovirale%20therapie%204-6%20weken%20na%20start%20%28polikliniek%29"&gt;Eerste controle na instellen op <span class="SpellE">anti-retrovirale</span> therapie 4-6 weken na start (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:26"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Controle%20van%20pati%C3%ABnten%20op%20antiretrovirale%20therapie%20%28polikliniek%29"&gt;Controle van patiënten op antiretrovirale therapie (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:27"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Controle%20van%20pati%C3%ABnten%20zonder%20antiretrovirale%20therapie%20%28polikliniek%29"&gt;Controle van patiënten zonder antiretrovirale therapie (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:28"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.2.%20Spiegelbepaling"&gt;4.2. Spiegelbepaling&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:29"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.3.%20Resistentiebepalingen"&gt;4.3. Resistentiebepalingen&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:30"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:31"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%205.%20Diagnostiek%20en%20behandeling%20primaire%20HIV-infectie"&gt;Hoofdstuk''' '''5. Diagnostiek en behandeling primaire <span class="SpellE">HIV-infectie</span>&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:32"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:33"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%206.%20Therapietrouw%20bevorderende%20maatregelen"&gt;Hoofdstuk''' '''6. Therapietrouw bevorderende maatregelen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:34"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/6.1.%20Therapietrouw%20be%C3%AFnvloedende%20factoren"&gt;6.1. Therapietrouw beïnvloedende factoren&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:35"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%206.1"&gt;Literatuur 6.1&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:36"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/6.2.%20Therapietrouw%20bevorderende%20interventies"&gt;6.2. Therapietrouw bevorderende interventies&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:37"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20therapietrouw%20bevorderende%20interventies"&gt;Onderbouwing therapietrouw bevorderende interventies&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:38"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%206.2"&gt;Literatuur 6.2&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:39"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:40"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%207.%20Preventie%20van%20moeder-kind%20overdracht:%20zwangerschap,%20bevalling%20en%20neonatale%20periode"&gt;Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale''' '''periode&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
+
-
NIH Perinatal</span>
+
-
 
+
-
<span style="mso-bidi-font-weight:bold">NVHB Richtlijn 2007</span>
+
-
 
+
-
|- style="mso-yfti-irow:41"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%207"&gt;Literatuur 7&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:42"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:43"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%208.%20HIV-2%20bij%20volwassenen:%20Behandeling%20en%20monitoring"&gt;Hoofdstuk''' '''8. HIV-2 bij volwassenen: Behandeling en monitoring&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
+
-
NIH</span>
+
-
 
+
-
|- style="mso-yfti-irow:44"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%208"&gt;Literatuur 8&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:45"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:46"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%209.%20Bijzondere%20omstandigheden"&gt;Hoofdstuk''' '''9. Bijzondere omstandigheden&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:47"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.1.%20Adviezen%20m.b.t.%20inname%20van%20anti-HIV%20middelen%20na%20braken"&gt;9.1. Adviezen m.b.t. inname van anti-HIV middelen na braken&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:48"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.2.%20Adviezen%20m.b.t.%20inname%20van%20anti-HIV%20middelen%20bij%20vergeten%20van%20slikmoment"&gt;9.2. Adviezen m.b.t. inname van anti-HIV middelen bij vergeten van slikmoment&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:49"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.3.%20Marge%20tussen%20twee%20innames"&gt;9.3. Marge tussen twee innames&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:50"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.4.%20Inname%20medicatie%20bij%20overschrijden%20tijdzones"&gt;9.4. Inname medicatie bij overschrijden tijdzones&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:51"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.5.%20Adviezen%20m.b.t.%20gebruik%20anti-HIV%20middelen%20door%20de%20sonde"&gt;9.5. Adviezen m.b.t. gebruik anti-HIV middelen door de sonde&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:52"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.6.%20Doseringen%20bij%20gestoorde%20lever-%20en%20nierfunctie"&gt;9.6. Doseringen bij gestoorde lever- en nierfunctie&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:53"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:54"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2010.%20Behandeling%20van%20hepatitis%20B/C-virus%20co%C3%AFnfectie%20bij%20HIV-1%20positieve%20pati%C3%ABnten"&gt;Hoofdstuk 10. Behandeling van hepatitis B/C-virus <span class="SpellE">coïnfectie</span>''' '''bij HIV-1 positieve patiënten&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:55"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.1.%20Hepatitis%20B"&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">10.1. Hepatitis B</span>&lt;/a&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">&lt;o:p&gt;&lt;/o:p&gt;</span>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
EACS
+
-
 
+
-
|- style="mso-yfti-irow:56"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.2.%20Hepatitis%20C%C2%A0%28acuut%29"&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">10.2. Hepatitis C&nbsp;(<span class="SpellE">acuut</span>)</span>&lt;/a&gt;<span lang="EN-US" style="mso-ansi-language: EN-US">&lt;o:p&gt;&lt;/o:p&gt;</span>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
NL aanbevelingen
+
-
 
+
-
NEAT
+
-
 
+
-
|- style="mso-yfti-irow:57"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Levels%20of%20evidence"&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">Levels of evidence</span>&lt;/a&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">&lt;o:p&gt;&lt;/o:p&gt;</span>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:58"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2010.2"&gt;Literatuur 10.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:59"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.3.%20Hepatitis%20C%C2%A0%28chronisch%29"&gt;10.3. Hepatitis C&nbsp;(chronisch)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
EACS
+
-
 
+
-
|- style="mso-yfti-irow:60"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:61"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2011.%20Behandeling%20van%20tuberculose%20bij%20pati%C3%ABnten%20met%20een%20HIV-infectie"&gt;Hoofdstuk''' '''11. Behandeling van tuberculose bij patiënten met een HIV-<span class="SpellE">infectie</span>&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:62"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2011"&gt;Literatuur 11&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:63"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:64"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2012.%20Comorbiditeit%20en%20bijwerkingen"&gt;Hoofdstuk''' '''12. Comorbiditeit en bijwerkingen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span style="mso-bidi-font-weight:bold">EACS</span>
+
-
 
+
-
|- style="mso-yfti-irow:65"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:66"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2013.%20Screening%20van%20HIV-pati%C3%ABnten%20op%20anogenitale%20maligniteiten"&gt;Hoofdstuk''' '''13. Screening van HIV-patiënten op anogenitale maligniteiten&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:67"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20screening%20van%20HIV-pati%C3%ABnten%20op%20anogenitale%20maligniteiten"&gt;Onderbouwing screening van HIV-patiënten op anogenitale maligniteiten&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:68"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2013"&gt;Literatuur 13&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:69"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:70"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2014.%20Interacties"&gt;Hoofdstuk''' '''14. Interacties&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:71"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:72"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2015.%20Profylaxe%20en%20behandeling%20van%20opportunistische%20infectie"&gt;Hoofdstuk''' '''15. Profylaxe en behandeling van opportunistische infectie&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:73"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:74"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
Hoofdstuk 16. Post Exposure Profylaxe na prikaccident en onveilig <span class="SpellE">sexueel</span> contact
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:75"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2016.%20Transmissiereductie%20%28PEP%29"&gt;Hoofdstuk''' '''16. <span class="GramE">Transmissiereductie</span> (PEP)&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:76"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/16.1.%20Prikaccidenten"&gt;16.1. Prikaccidenten&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
LCI
+
-
 
+
-
|- style="mso-yfti-irow:77"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/16.2.%20Seksaccidenten"&gt;16.2. Seksaccidenten&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
LCI/RIVM
+
-
 
+
-
|- style="mso-yfti-irow:78"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:79"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2017.%20Vaccinatiebeleid"&gt;Hoofdstuk''' '''17. Vaccinatiebeleid&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:80"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.1.%20Vaccinaties%20bij%20HIV-ge%C3%AFnfecteerde%20kinderen"&gt;17.1. Vaccinaties bij <span class="SpellE">HIV-geïnfecteerde</span> kinderen&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
CDC
+
-
 
+
-
|- style="mso-yfti-irow:81"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.2.%20Vaccinatie%20tegen%20influenza"&gt;17.2. Vaccinatie tegen influenza&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
NHG Standaard
+
-
 
+
-
|- style="mso-yfti-irow:82"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20Vaccinatie%20tegen%20influenza"&gt;Onderbouwing Vaccinatie tegen influenza&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:83"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2017.2"&gt;Literatuur 17.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:84"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.3.%20Vaccinatie%20tegen%20infecties%20met%20Streptococcus%20pneumoniae%20%28Pneumokokken%29"&gt;17.3. Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:85"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20Vaccinatie%20tegen%20infecties%20met%20Streptococcus%20pneumoniae%20%28Pneumokokken%29%20%28Pneumokokken%29"&gt;Onderbouwing Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken) (Pneumokokken)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:86"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2017.3"&gt;Literatuur 17.3&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:87"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.4.%20Vaccinaties%20tegen%20Hepatitis%20A%20en%20B"&gt;17.4. Vaccinaties tegen Hepatitis A en B&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:88"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.5.%20Vaccinatie%20bij%20HIV-ge%C3%AFnfecteerde%20reizigers"&gt;17.5. Vaccinatie bij <span class="SpellE">HIV-geïnfecteerde</span><span class="SpellE">reizigers</span>&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
LCR
+
-
 
+
-
CDC
+
-
 
+
-
|- style="mso-yfti-irow:89"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bureau%27s%20voor%20reizigersadvisering"&gt;<span class="SpellE">Bureau's</span> voor reizigersadvisering&lt;/a&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:90"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:91;mso-yfti-lastrow:yes"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2018.%20Kostenoverzicht%20antiretrovirale%20middelen"&gt;Hoofdstuk''' '''18. Kostenoverzicht antiretrovirale middelen&lt;/a&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|}
+
-
 
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt; &lt;/div&gt; &lt;/body&gt;&lt;/html&gt;
+

Huidige versie per 9 nov 2023 17:48

In onderstaande lijst staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld:

Antiretrovirale therapie bij volwassenen
Wanneer beginnen?: DHHS
Keuze van antiretrovirale behandeling bij naïeve volwassen met hiv: DHHS
Tijdelijk onderbreken van antiretrovirale behandeling: DHHS
Antiretrovirale behandeling bij voorbehandelde mensen met hiv: DHHS
Monitoring: DHHS
Controles van mensen met hiv (polikliniek)
Bij eerste consult bij mensen met hiv
Eerste controle bij therapie-naïeve mensen na start van de antiretrovirale behandeling, 4-6 weken na start (op indicatie)
Controle van mensen met antiretrovirale behandeling
Controle van mensen zonder antiretrovirale behandeling
Spiegelbepaling: EACS
Resistentiebepalingen: DHHS
Diagnostiek en behandeling acute hiv-infectie: DHHS
Therapietrouwbevordering
Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode: DHHS, Landelijk HIV expositieprotocol neonaten, inclusief follow-up pasgeborene en kind
Hiv-2 bij volwassenen: behandeling en monitoring
Bijzondere omstandigheden
Adviezen m.b.t. inname van anti-hiv middelen na braken
Adviezen m.b.t. inname van anti-hiv middelen bij vergeten van slikmoment
Marge tussen twee innames
Inname medicatie bij overschrijden tijdzones
Adviezen m.b.t. gebruik anti-hiv middelen door de sonde
Doseringen bij gestoorde leverfunctie
Doseringen bij gestoorde nierfunctie
Adviezen m.b.t. hiv-therapie bij mensen met een gastric bypass
Behandeling van hepatitis B/C virus coïnfectie bij mensen met hiv-1
Hepatitis B: HBV richtsnoer
Hepatitis C: HCV richtsnoer
HCC surveillance: HBV richtsnoer
Behandeling van tuberculose bij mensen met een hiv-infectie:CPT
Screening en comorbiditeit
Screening cervixcarcinoom: CIN
Screening anale premaligne afwijkingen
Screening overige comorbiditeit en bijwerkingen: EACS
Geneesmiddeleninteracties: EACS
Profylaxe en behandeling van opportunistische infecties: DHHS, nationale antibioticaboekje, SWAB, NVvP
Transmissiemanagement
Prikaccidenten: LCI
Seksaccidenten: LCI
Discordante koppels
Vaccinatiebeleid
Influenza: RIVM
Streptococcus pneumoniae (pneumokokken): DHHS
Hepatitis A en B: RIVM
Reizigers met hiv
Varicellazostervirus
COVID-19: RIVM
Reizigersadvisering
Inname medicatie bij overschrijden tijdzones
Vaccinatie en profylaxe bij reizigers met hiv

Achtergrondinformatie over de richtlijn en totstandkoming

Samenstelling werkgroep
Overzicht belangen werkgroepleden
Doelen en werkwijze
Wijzigingsoverzichten van de richtlijn
Lijst met verwijzingen naar andere richtlijnen

Teruggeplaatst van "https://richtlijnhiv.nvhb.nl/index.php/Lijst_met_verwijzingen_naar_andere_richtlijnen"